Several other research firms have also recently issued reports on AXON. HC Wainwright reissued a buy rating on shares of Axovant Sciences in a research note on Wednesday, August 17th. JMP Securities reissued an outperform rating and issued a $36.00 price target on shares of Axovant Sciences in a research note on Tuesday, August 16th. Zacks Investment Research raised Axovant Sciences from a hold rating to a buy rating and set a $17.00 price target for the company in a research note on Monday, August 8th. Piper Jaffray Cos. set a $32.00 price target on Axovant Sciences and gave the stock a buy rating in a research note on Friday, September 23rd. Finally, Leerink Swann assumed coverage on Axovant Sciences in a research note on Tuesday, June 7th. They issued an outperform rating and a $22.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Axovant Sciences currently has a consensus rating of Buy and a consensus target price of $25.21.
Shares of Axovant Sciences (NYSE:AXON) opened at 14.59 on Friday. The company’s 50-day moving average price is $15.95 and its 200-day moving average price is $13.51. The stock’s market cap is $1.45 billion. Axovant Sciences has a 52-week low of $8.86 and a 52-week high of $21.30.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.02. Analysts expect that Axovant Sciences will post ($1.69) earnings per share for the current year.
Several large investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its stake in shares of Axovant Sciences by 68.6% in the second quarter. California State Teachers Retirement System now owns 51,249 shares of the company’s stock valued at $658,000 after buying an additional 20,859 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Axovant Sciences by 39.3% in the second quarter. Bank of New York Mellon Corp now owns 72,198 shares of the company’s stock valued at $928,000 after buying an additional 20,368 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new stake in shares of Axovant Sciences during the second quarter valued at approximately $682,000. Alps Advisors Inc. increased its stake in shares of Axovant Sciences by 24.9% in the second quarter. Alps Advisors Inc. now owns 139,286 shares of the company’s stock valued at $1,788,000 after buying an additional 27,780 shares in the last quarter. Finally, Strs Ohio increased its stake in shares of Axovant Sciences by 960.9% in the second quarter. Strs Ohio now owns 48,800 shares of the company’s stock valued at $626,000 after buying an additional 44,200 shares in the last quarter. 29.45% of the stock is owned by institutional investors and hedge funds.
Axovant Sciences Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.